20230825-国海证券-凯因科技-688687.SH-2023年半年报点评报告_凯力唯高速增长_研发快速推进_5页_385kb

Key points from the Guohai Securities report on Kaicin Pharmaceutical (688687):

• Revenue Growth: The company's revenue surged by 1539% year-on-year in 2023 H1, driven by the Keliwei product, which now covers major viral hepatitis genotypes after医保 expansion.
• R&D Investment: R&D expenses totaled 561.4 million CNY (9.87% of revenue), with key trials, like Kailijinfusin for chronic HBV, advancing to follow-up phase.
• Financial Forecast: Expected revenue of 15.13 billion CNY, 19.90 billion CNY, and 25.50 billion CNY for 2023-2025, with corresponding net profits and decreasing PE ratios.
• Investment Rating: Maintain "Buy" based on high growth potential in viral hepatitis and innovative drugs.
• Risks: Potential delays in drug development, market promotion issues, price pressure from医保 negotiations, and reduced market share if products face tender processes.